Dravet Syndrome clinical trials at UCLA

4 in progress, 1 open to eligible people

Showing trials for

  • LP352 in Children and Adults With Dravet Syndrome (DS)

    open to eligible people ages 2-65

    This (DEEp SEA Study) is a double-blind, randomized, placebo-controlled, multicenter study to investigate the efficacy, safety, and tolerability of LP352 in the treatment of seizures in children and adults with DS. The study consists of 3 main phases: Screening, Titration period, and Maintenance period, followed by a Taper period and Follow-Up. Participants will be randomized to LP352 or placebo. The total duration of the study will be approximately 24 months.

    Los Angeles 5368361, California 5332921 and other locations

  • Intermediate-Size Expanded Access Protocol (EAP) for LP352

    Sorry, not accepting new patients

    This is an intermediate-size expanded access program (EAP) study. The purpose of this EAP is to provide continued access to LP352, an investigational drug product being investigated in participants with DEEs. The EAP study will allow continued treatment with LP352 for eligible participants diagnosed with treatment resistant DEEs who successfully completed an LP352 Clinical Trial (Enrollment by Invitation) or an immediate family member who has the exact same gene mutation resulting in the same DEE epilepsy syndrome phenotype or a patient who previously participated in the lorcaserin EAP.

    Los Angeles 5368361, California 5332921 and other locations

  • Access Program With Lorcaserin For The Treatment of Dravet Syndrome and Other Refractory Epilepsies

    Sorry, not accepting new patients

    The primary purpose of this study is to provide continued access of lorcaserin to participants with Dravet syndrome and other refractory epilepsies.

    Los Angeles 5368361, California 5332921 and other locations

  • Treatment of Dravet Syndrome With Fenfluramine (Expanded Access Protocol)

    Sorry, not accepting new patients

    The purpose of this research study is to (1) provide access to fenfluramine for patients with intractable epilepsy associated with Dravet syndrome, and (2) evaluate the safety of fenfluramine.

    Los Angeles 5368361, California 5332921

Our lead scientists for Dravet Syndrome research studies include .

Last updated: